A cancer patient is in a state of fear and openness.
In the weeks following a podcast appearance by actor Mel Gibson, pharmacies across the country recorded a 250 percent surge in ivermectin prescriptions among cancer patients — a drug developed for parasitic infections with no clinical evidence supporting its use against tumors. The moment illuminates something enduring and fragile about human hope: that when medicine feels uncertain, the voice of a familiar face in a vast digital room can carry more weight than years of clinical research. What is at stake is not merely the choice of one drug over another, but the time that cancer does not forgive.
- A single podcast appearance by Mel Gibson on Joe Rogan's platform triggered a 250% spike in ivermectin prescriptions among cancer patients within weeks — a measurable, documented shift in medical behavior driven by celebrity, not evidence.
- Ivermectin has no clinical trials supporting its use against cancer, yet patients — many desperate after conventional treatments failed — began requesting it from doctors, some of whom wrote the prescriptions.
- Public health officials and medical researchers tracking prescription patterns flagged the surge as a potential crisis, not because the drug is inherently dangerous, but because pursuing it may mean abandoning chemotherapy, radiation, or immunotherapy during critical treatment windows.
- Pharmacists and oncologists found themselves in difficult conversations with patients who had already decided, arriving not with questions but with conviction borrowed from a podcast.
- The episode exposes a structural vulnerability in modern medical decision-making: platforms that reach millions grant a casual, unearned authority to public figures who need no credentials to reshape how sick people understand their options.
In May, pharmacies across the country began filling ivermectin prescriptions at an unusual rate. The antiparasitic drug — developed to treat parasitic infections in humans and animals — saw a 250 percent jump in cancer-related prescriptions in the weeks after actor Mel Gibson promoted it on Joe Rogan's podcast. Ivermectin is not a cancer drug. It has no clinical evidence supporting its use against malignant tumors. Yet cancer patients, many of them desperate, began asking their doctors for it. Some doctors obliged.
The mechanism of influence is straightforward and troubling. Rogan's podcast reaches millions each week, and Gibson — a recognizable figure with decades of Hollywood credibility — spoke with apparent conviction. For someone newly diagnosed, or someone whose conventional treatments have failed, that combination creates a powerful pull. The listener may not know that ivermectin was developed for parasites, or that no clinical trials support its use for cancer. They hear a famous person say it works, and they want to try it.
The deeper concern among doctors and public health officials is not merely that patients are taking an ineffective drug — it is that they may be taking it instead of treatments that work. Time matters in cancer. A patient spending weeks pursuing ivermectin is a patient not undergoing chemotherapy, radiation, or immunotherapy. Delay can mean the difference between a treatable stage and one that has progressed beyond reach.
Pharmacists and oncologists began reporting conversations with patients who had already decided before walking through the door. The prescriptions that followed are now part of the medical record — data tracking how information, accurate or not, moves through a population and reshapes behavior. The 250 percent spike is a question written in pharmacy records: in an era when anyone with an audience can speak about health, how do we protect people who are sick and searching from endorsements that sound plausible but carry no foundation?
In May of this year, pharmacies across the country began filling prescriptions for ivermectin at an unusual rate. The antiparasitic drug, developed decades ago to treat parasitic infections in humans and animals, saw its prescription volume for cancer patients jump by 250 percent in the weeks following a podcast appearance by actor Mel Gibson. On Joe Rogan's widely listened platform, Gibson had promoted ivermectin as a cancer treatment, and the effect was immediate and measurable.
Ivermectin is not a cancer drug. It has no clinical evidence supporting its use against malignant tumors. The medical establishment has not endorsed it for this purpose. Yet cancer patients, many of them desperate and searching for any possible avenue of hope, began asking their doctors for prescriptions. Some doctors obliged. The surge in demand was sharp enough that it caught the attention of public health officials and medical researchers tracking prescription patterns.
The mechanism of influence here is straightforward and troubling. Joe Rogan's podcast reaches millions of listeners each week. Gibson, a recognizable figure with decades of Hollywood credibility, spoke with apparent conviction about the drug's potential. For someone newly diagnosed with cancer, or someone whose conventional treatments have failed, the combination of celebrity endorsement and a massive audience creates a powerful pull. The listener does not necessarily know that ivermectin lacks clinical trials for cancer. They may not know that the drug was originally developed for parasites. They hear a famous person say it works, and they want to try it.
What makes this particular moment significant is what it reveals about how medical decisions get made in the modern era. A person with cancer used to rely primarily on their oncologist, their family, and perhaps a few trusted sources of medical information. Now they also contend with podcasts, social media, and the casual authority that comes with being a public figure with a microphone. Gibson did not present himself as a medical expert. But he did not need to. The platform itself confers a kind of credibility.
The concern among doctors and public health officials is not merely that patients are taking an ineffective drug. It is that they may be taking it instead of treatments that work. A cancer patient who spends weeks or months pursuing ivermectin is a patient not undergoing chemotherapy, radiation, surgery, or immunotherapy—the interventions with actual evidence behind them. Time matters in cancer treatment. Delay can mean the difference between a treatable stage and one that has progressed beyond reach. The 250 percent spike in prescriptions represents not just a curiosity or a harmless alternative, but a potential public health consequence.
Pharmacists and doctors began reporting conversations with patients who had heard about ivermectin on the Rogan podcast and wanted to know if it could help them. Some patients had already decided they would try it. Others were asking whether it could be used alongside their existing treatment plan. The prescriptions that resulted are now part of the medical record, part of the data that tracks how information—accurate or not—moves through a population and shapes behavior.
This moment sits at the intersection of celebrity culture, digital media, and medical vulnerability. It raises a question that will likely persist: in an era when anyone with an audience can speak about health, how do we protect people who are sick and searching for answers from endorsements that sound plausible but lack foundation? The 250 percent spike in ivermectin prescriptions is the answer written in pharmacy records.
Citações Notáveis
Gibson promoted ivermectin as a cancer treatment on the widely listened platform, and the effect was immediate and measurable.— Medical records and prescription tracking data
A Conversa do Hearth Outra perspectiva sobre a história
Why did Gibson's endorsement move the needle so dramatically? What made people actually go to their doctors and ask for this?
Because he said it with certainty, and he said it to millions of people at once. A cancer patient is in a state of fear and openness. They're looking for anything. When someone famous says 'this works,' that lands differently than a clinical trial abstract.
But didn't people know it was an antiparasitic drug? Didn't that seem odd?
Maybe some did. But the podcast format doesn't encourage that kind of critical distance. You're listening to a conversation, not reading a peer-reviewed paper. It feels intimate, like someone's sharing something they've discovered.
So the real problem isn't ivermectin itself—it's what patients might be skipping?
Exactly. A patient spending three months on ivermectin is three months not in chemotherapy. In cancer, time is tissue. That's where the harm lives.
Could a doctor have just said no?
Some did. But others felt caught between dismissing a patient's hope and endorsing something unproven. And some doctors themselves may have heard the same podcast.
What happens to these patients now?
That's the question nobody can answer yet. Some will realize it's not working and return to conventional treatment. Others may have already lost time they couldn't afford to lose.